RICHMOND HILL, Ontario, Oct. 16, 2018 (GLOBE NEWSWIRE) -- Helix BioPharma Corp. (TSX, FSE: HBP) ("Helix" or the "Company"), an immuno-oncology company developing innovative drug candidates for the ...
In connection with the proposed adoption of the Incentive Program, the Company also announces that it is extending the exercise period of a total of 3,680,000 Warrants (the "Extended Warrants"), all ...
Helix Resources Limited ( ($AU:HLX) ) has issued an announcement. Helix Resources Limited has reported the expiry of a series of listed options on ...
BOSTON--(BUSINESS WIRE)-- Helix Acquisition Corp. II (Nasdaq: HLXB) (the “Company”) announced today that on February 13, 2024 it closed the initial public offering of 18,400,000 Class A ordinary ...